The results of the seventh batch of national centralized drug procurement will be announced.
On July 14, Taiji Group, Peking University Pharmaceuticals, Tiansheng Pharmaceuticals, and Fuan Pharmaceuticals, four listed Chongqing pharmaceutical companies announced that a total of 7 products were shortlisted and obtained the qualifications to be selected.
1 each from Tai Chi Group and Tiansheng Pharmaceutical
Peking University Medicine has 2
Upstream news reporters learned that on July 13, the State Organization Drug Joint Procurement Office released the results of the seventh batch of national centralized drug procurement to be announced.
The drug “Caffeine Citrate Caffeine Injection” of Southwest Pharmaceutical, a subsidiary of Taiji Group, is planned to be selected. The proposed price is 69.53 yuan per box, and the number of bids to be won is 126,500. The proposed supply includes Sichuan Province, Guizhou Province, Chongqing City, and Tianjin City. , Jilin Province, Zhejiang Province and Hainan Province, the procurement cycle is three years. Caffeine citrate injection is mainly used for the treatment of primary apnea in premature neonates. The declared specification of the drug is 1ml:20mg, and the packaging quantity is 2 pieces/box.
According to reports, the drug caffeine citrate injection that Southwest Pharmaceuticals plans to win the bid will obtain the “Drug Registration Certificate” issued by the State Food and Drug Administration in April 2021. The drug will have no sales revenue in 2021; the sales revenue in the first half of 2022 will be 63,700 yuan.
Two varieties of “Cefminox Sodium for Injection” and “Meropenem for Injection” of Peking University Medicine are planned to be collected for the second time. The selected prices are 63.60 yuan and 9.33 yuan respectively.
It is understood that cefminox sodium for injection is suitable for septicemia, tonsillitis, acute bronchitis caused by Streptococcus, Streptococcus pneumoniae, Escherichia coli, Klebsiella, Haemophilus influenzae, etc. inflammation, pneumonia, lung abscess, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, peritonitis, cholecystitis, intrauterine infection, etc. The drug specification is 1g, and the packaging quantity is 8 bottles/box.
Meropenem for injection is suitable for pneumonia, urinary tract infection, gynecological infection, skin and soft tissue infection, intra-abdominal infection, meningitis, sepsis, etc. caused by single or multiple meropenem-sensitive bacteria in adults and children. This product can be used alone. Or combined with antiviral or antifungal drugs. The medicine specification is 0.5g, and the packaging quantity is 1 bottle/box.
Hubei Tiansheng “Lidocaine Hydrochloride Injection”, a wholly-owned subsidiary of Tiansheng Pharmaceutical, is to be selected. The proposed winning bid price is 13.10 yuan/box, and the procurement cycle is three years. Lidocaine hydrochloride injection is a local anesthetic and antiarrhythmic drug, mainly used for infiltration anesthesia, epidural anesthesia, topical anesthesia (including mucosal anesthesia during thoracoscopy or abdominal surgery) and nerve conduction block; It can be used for ventricular premature beats and ventricular tachycardia after acute myocardial infarction, and can also be used for ventricular arrhythmia caused by digitalis poisoning, cardiac surgery and cardiac catheterization. The drug specification is 5ml: 0.1g, and the packaging quantity is 5 pieces/box.
It is reported that the proposed product, lidocaine hydrochloride injection, passed the quality and efficacy consistency evaluation of generic drugs in July 2021; in 2021, the product achieved sales revenue of 28.3212 million yuan, accounting for about 3.84%.
Fu’an Pharmaceutical’s three drugs to be selected
Fu’an Pharmaceutical is the biggest winner, and its subsidiaries Hubei People’s Pharmaceutical Co., Ltd. (People’s Pharmaceutical), Qingyutang Pharmaceutical Co., Ltd. (Qingyutang), and Tianheng Pharmaceutical Co., Ltd. (Tianheng Pharmaceutical) were selected this time. Collection.
People’s Pharmaceuticals plans to select tigecycline for injection (4 types of chemical drugs), with a proposed price of 29.36 yuan, mainly for Zhejiang, Sichuan, Jilin and Gansu, and for Shanghai, Guangdong, Chongqing and Guizhou. The pharmaceutical company achieved sales revenue of 18.4666 million yuan in 2021, accounting for 0.75%. The drug is indicated for the treatment of complex skin and skin structure infections (cSSSI), complex intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia in adult patients 18 years of age and older. The specification of this variety is 50mg, and the packaging specification is 1 bottle/box.
Tianheng Pharmaceutical plans to select the selected variety is Ondansetron Hydrochloride Injection (4 types of chemical drugs), the proposed price is 94.90 yuan, mainly for Zhejiang, Sichuan, Hebei, Chongqing, Liaoning, Fujian, Hainan, Tibet, and Guangdong for the supply area , Shanghai, Hunan, Shandong, Yunnan, Guizhou, Qinghai, etc. The pharmaceutical company achieved sales revenue of 41.6097 million yuan in 2021, accounting for 1.70%. The drug is mainly used to control nausea and vomiting caused by cancer chemotherapy and radiation therapy, and is also suitable for prevention and postoperative nausea and vomiting. The specification of this variety is 4ml:8mg, and the packaging specification is 5 pieces/box.
Qingyutang plans to select cefmetazole sodium for injection (category 4 chemical drugs), the proposed price is 133.33 yuan and 226.66 yuan respectively, mainly for Jiangsu, Hebei, Gansu, Shanxi, Hubei, Yunnan, Guizhou, etc. . The pharmaceutical company achieved sales revenue of 22.9669 million yuan in 2021, accounting for 0.94%. This drug is mainly suitable for sepsis, bronchitis, bronchiectasis infection caused by sensitive bacteria, pneumonia, secondary infection of chronic respiratory diseases, pulmonary suppura (lung abscess), empyema, cholangitis, cholecystitis, peritonitis, pyelonephritis , cystitis, bartholinitis, intrauterine infection, etc. The medicine is available in two sizes, 0.5g and 1.0g, and the packaging size is 10 bottles/box.
The four listed companies all stated that this centralized procurement is the seventh batch of centralized drug procurement organized by the state. During the procurement cycle, medical institutions will give priority to using the selected drugs in this centralized drug procurement and ensure that the agreed procurement volume is completed. If the company signs and implements the procurement contract in the future, it will further expand the sales of related products, increase the market share, and have a positive impact on enhancing the company’s brand influence.
Upstream news reporter Liu Yong intern Fu DongReturn to Sohu, see more
Editor:
Disclaimer: The opinions of this article only represent the author himself, Sohu is an information publishing platform, and Sohu only provides information storage space services.